|
gptkbp:instanceOf
|
gptkb:drug
gptkb:antihypertensive_agent
|
|
gptkbp:approvedBy
|
1960
|
|
gptkbp:ATCCode
|
C02AB01
|
|
gptkbp:brand
|
Aldomet
Aldoril
|
|
gptkbp:CASNumber
|
555-30-6
|
|
gptkbp:chemicalFormula
|
C10H13NO4
|
|
gptkbp:contraindication
|
MAO inhibitor use
active hepatic disease
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:drugClass
|
gptkb:alpha-2_adrenergic_agonist
|
|
gptkbp:eliminationHalfLife
|
1.5–2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
centrally acting alpha-2 adrenergic agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
211.22 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
gptkb:anemia
headache
drowsiness
dry mouth
liver dysfunction
|
|
gptkbp:usedFor
|
treatment of hypertension
|
|
gptkbp:usedInPregnancy
|
yes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:autoimmune_hemolytic_anemia
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
methyldopa
|